Entrada Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Entrada Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q2 2024.
  • Entrada Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 72.3 %, a 3.88% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 72.3 +2.7 +3.88% Jun 30, 2024
Q1 2024 103 +63.6 +162% Mar 31, 2024
Q4 2023 108 +91.5 +560% Dec 31, 2023
Q3 2023 90.5 +78.6 +656% Sep 30, 2023
Q2 2023 69.6 +57.2 +463% Jun 30, 2023
Q1 2023 39.4 Mar 31, 2023
Q4 2022 16.3 Dec 31, 2022
Q3 2022 12 Sep 30, 2022
Q2 2022 12.4 Jun 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.